Publications by authors named "Lesley Murray"

Claim this Profile
I
Impact on stakeholders of a cultural adaptation of a social and emotional well-being intervention in an Aboriginal community.
Robert J Donovan, Catherine F Drane, Julie Owen, Lesley Murray, Amberlee Nicholas

Health Promot J Austr· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation.
Michael Lowe, Lesley Murray, Alok Tyagi, George Gorrie, Sarah Miller

J Headache Pain· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a culturally appropriate branding for a social and emotional wellbeing intervention in an Aboriginal community.
Robert J Donovan, Lesley Murray, Jolleen Hicks, Amberlee Nicholas, Julia Anwar-McHenry

Health Promot J Austr· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling.
Huifen Chen, Matthew Volgraf, Steven Do, Aleksandr Kolesnikov, Daniel G Shore, Lesley J Murray

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat.
Peter W Fan, Jacob Z Chen, M Allan Jaochico, Hank La, Ning Liu, Lesley J Murray

Drug Metab Lett· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Jun Liang, Sharada Labadie, Birong Zhang, Daniel F Ortwine, Snahel Patel, Lesley Murray

Bioorg Med Chem Lett· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Sharada S Labadie, Peter S Dragovich, Richard T Cummings, Gauri Deshmukh, Amy Gustafson, Lesley Murray

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
Wendy Lee, James J Crawford, Ignacio Aliagas, Lesley J Murray, Suzanne Tay

Bioorg Med Chem Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Jun Liang, Birong Zhang, Sharada Labadie, Daniel F Ortwine, Maia Vinogradova, Lesley Murray

Bioorg Med Chem Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
Joachim Rudolph, Lesley J Murray, Chudi O Ndubaku, Thomas O'Brien, Elizabeth Blackwood

J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.
Chudi O Ndubaku, James J Crawford, Joy Drobnick, Ignacio Aliagas, David Campbell, Lesley J Murray

ACS Med Chem Lett· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis.
Chudi O Ndubaku, Terry D Crawford, Huifen Chen, Jason W Boggs, Joy Drobnick, Lesley J Murray

ACS Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
James J Crawford, Wendy Lee, Ignacio Aliagas, Simon Mathieu, Klaus P Hoeflich, Lesley Murray

J Med Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.
Joachim Rudolph, Ignacio Aliagas, James J Crawford, Simon Mathieu, Wendy Lee, Lesley J Murray

ACS Med Chem Lett· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
Lan Wang, Mark Stanley, Jason W Boggs, Terry D Crawford, Brandon J Bravo, Lesley J Murray

Bioorg Med Chem Lett· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
Terry D Crawford, Chudi O Ndubaku, Huifen Chen, Jason W Boggs, Brandon J Bravo, Lesley J Murray

J Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare neurological diseases: a practical approach to management.
Krishna A Dani, Lesley J Murray, Saif Razvi

Pract Neurol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
John A Flygare, Maureen Beresini, Nageshwar Budha, Helen Chan, Iris T Chan, Lesley Murray

J Med Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
Josef R Bencsik, Dengming Xiao, James F Blake, Nicholas C Kallan, Ian S Mitchell, Lesley J Murray

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.
Georgette M Castanedo, Shumei Wang, Kirk D Robarge, Elizabeth Blackwood, Daniel Burdick, Lesley Murray

Bioorg Med Chem Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GDC-0449-a potent inhibitor of the hedgehog pathway.
Kirk D Robarge, Shirley A Brunton, Georgette M Castanedo, Yong Cui, Michael S Dina, Lesley J Murray

Bioorg Med Chem Lett· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Klaus P Hoeflich, Carol O'Brien, Zachary Boyd, Guy Cavet, Steve Guerrero, Lesley Murray

Clin Cancer Res· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, Tom Truong, Peter M Haverty, Lesley J Murray

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Harvey Wong, Marcia Belvin, Sylvia Herter, Klaus P Hoeflich, Lesley J Murray

J Pharmacol Exp Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Klaus P Hoeflich, Sylvia Herter, Janet Tien, Leo Wong, Leanne Berry, Lesley Murray

Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis